NO20006352L - Anvendelse av diazepiner til fremstilling av medisiner for behandling av patologiske tilstander eller sykdommer som involverer en av veksthormon-frigjöringsinhiberingsfaktor- reseptorene - Google Patents
Anvendelse av diazepiner til fremstilling av medisiner for behandling av patologiske tilstander eller sykdommer som involverer en av veksthormon-frigjöringsinhiberingsfaktor- reseptorene Download PDFInfo
- Publication number
- NO20006352L NO20006352L NO20006352A NO20006352A NO20006352L NO 20006352 L NO20006352 L NO 20006352L NO 20006352 A NO20006352 A NO 20006352A NO 20006352 A NO20006352 A NO 20006352A NO 20006352 L NO20006352 L NO 20006352L
- Authority
- NO
- Norway
- Prior art keywords
- diazepines
- treatment
- medicaments
- manufacture
- pathological conditions
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 2
- 230000001575 pathological effect Effects 0.000 title claims 2
- 101000632994 Homo sapiens Somatostatin Proteins 0.000 title 1
- 102100029563 Somatostatin Human genes 0.000 title 1
- 150000004908 diazepines Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229960000553 somatostatin Drugs 0.000 title 1
- 108700021154 Metallothionein 3 Proteins 0.000 claims 1
- 102100028708 Metallothionein-3 Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9807509A FR2779652B1 (fr) | 1998-06-15 | 1998-06-15 | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| PCT/FR1999/001422 WO1999065917A1 (fr) | 1998-06-15 | 1999-06-15 | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20006352L true NO20006352L (no) | 2000-12-13 |
| NO20006352D0 NO20006352D0 (no) | 2000-12-13 |
Family
ID=9527389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006352A NO20006352D0 (no) | 1998-06-15 | 2000-12-13 | Anvendelse av diazepiner til fremstilling av medisiner for behandling av patologiske tilstander eller sykdommer som involverer en av veksthormon-frigjöringsinhiberingsfaktor- reseptorene |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7015213B1 (es) |
| EP (1) | EP1087978A1 (es) |
| JP (1) | JP2002518400A (es) |
| KR (1) | KR20010052836A (es) |
| CN (1) | CN100348600C (es) |
| AR (1) | AR019669A1 (es) |
| AU (1) | AU758206B2 (es) |
| CA (1) | CA2335724A1 (es) |
| FR (1) | FR2779652B1 (es) |
| HK (1) | HK1039780A1 (es) |
| HU (1) | HUP0102300A3 (es) |
| IL (1) | IL139954A0 (es) |
| MY (1) | MY118652A (es) |
| NO (1) | NO20006352D0 (es) |
| NZ (1) | NZ509313A (es) |
| PL (1) | PL344831A1 (es) |
| RU (1) | RU2229299C2 (es) |
| TW (1) | TW513434B (es) |
| WO (1) | WO1999065917A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6987105B2 (en) * | 2000-04-28 | 2006-01-17 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of thienotriazolodiazepines |
| WO2002057241A1 (en) * | 2000-12-22 | 2002-07-25 | Bayer Pharmaceuticals Corporation | 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES |
| WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
| BR112012029057A2 (pt) | 2010-05-14 | 2020-10-13 | Dana-Farber Cancer Institute, Inc. | composições e métodos de tratamento de leucemia |
| CA2799381A1 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Male contraceptive compositions and methods of use |
| EP2902030B1 (en) | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| EP2864336B1 (en) | 2012-06-06 | 2016-11-23 | Constellation Pharmaceuticals, Inc. | Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
| RU2016134947A (ru) | 2014-01-31 | 2018-03-01 | Дана-Фарбер Кансер Институт, Инк. | Производные диаминопиримидин бензолсульфона и их применение |
| JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体の使用 |
| WO2015131113A1 (en) * | 2014-02-28 | 2015-09-03 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
| EP3157928B1 (en) | 2014-06-20 | 2019-02-13 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
| JP2017525759A (ja) | 2014-08-08 | 2017-09-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジヒドロプテリジノン誘導体およびその使用 |
| JP2017526741A (ja) | 2014-08-08 | 2017-09-14 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体およびその使用 |
| WO2016069578A1 (en) | 2014-10-27 | 2016-05-06 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| BR112018004617A2 (pt) | 2015-09-11 | 2018-09-25 | Dana Farber Cancer Inst Inc | acetamida tienotriazoldiazepinas e usos das mesmas |
| RU2750164C2 (ru) * | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Цианотиенотриазолодиазепины и пути их применения |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| JOP20200030A1 (ar) * | 2017-09-07 | 2020-02-12 | Eisai R&D Man Co Ltd | مركب خماسي الحلقة |
| AU2020233452A1 (en) | 2019-03-05 | 2021-09-02 | Eisai R&D Management Co., Ltd. | Salt of pentacyclic compound and crystals thereof |
| EA202191966A1 (ru) | 2019-03-05 | 2021-12-08 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Пентациклическое гетероциклическое соединение |
| CN111533745A (zh) * | 2020-05-20 | 2020-08-14 | 成都药明康德新药开发有限公司 | 叔丁基-3-(氨基甲基)二氢-5h-三唑并二氮杂卓-8(9h)-甲酸基酯制法 |
| AU2021379248A1 (en) | 2020-11-16 | 2023-06-22 | Boehringer Ingelheim International Gmbh | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists |
| US11992494B2 (en) | 2021-12-22 | 2024-05-28 | Boehringer Ingelheim International Gmbh | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI95708C (fi) * | 1988-10-31 | 1996-03-11 | Eisai Co Ltd | Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi |
| GB8907256D0 (en) * | 1989-03-31 | 1989-05-17 | Rech Et D Applic Scient Scras | New derivatives of hetrazepine as anti-asthmatic anti-allergic and gastro-intestinal protectors |
| OA09202A (fr) * | 1990-04-02 | 1992-06-30 | Sod Conseils Rech Applic | Procédé de préparation des nouveaux dérivés de la thiéno-triazolo-diazépine. |
| DE4107521A1 (de) * | 1991-03-08 | 1992-09-10 | Boehringer Ingelheim Kg | Neue acylaminosubstituierte hetrazepine |
| EP0638560A4 (en) * | 1991-10-11 | 1995-03-29 | Yoshitomi Pharmaceutical | MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *. |
| AU4772497A (en) * | 1996-10-31 | 1998-05-22 | Novo Nordisk A/S | Constrained somatostatin agonists and antagonists |
-
1998
- 1998-06-15 FR FR9807509A patent/FR2779652B1/fr not_active Expired - Fee Related
-
1999
- 1999-06-15 JP JP2000554742A patent/JP2002518400A/ja active Pending
- 1999-06-15 RU RU2001101481/15A patent/RU2229299C2/ru not_active IP Right Cessation
- 1999-06-15 AU AU41495/99A patent/AU758206B2/en not_active Ceased
- 1999-06-15 US US09/701,893 patent/US7015213B1/en not_active Expired - Fee Related
- 1999-06-15 CN CNB998087092A patent/CN100348600C/zh not_active Expired - Fee Related
- 1999-06-15 WO PCT/FR1999/001422 patent/WO1999065917A1/fr not_active Application Discontinuation
- 1999-06-15 NZ NZ509313A patent/NZ509313A/xx unknown
- 1999-06-15 IL IL13995499A patent/IL139954A0/xx not_active IP Right Cessation
- 1999-06-15 AR ARP990102861A patent/AR019669A1/es unknown
- 1999-06-15 KR KR1020007014166A patent/KR20010052836A/ko not_active Application Discontinuation
- 1999-06-15 MY MYPI99002451A patent/MY118652A/en unknown
- 1999-06-15 EP EP99925093A patent/EP1087978A1/fr not_active Withdrawn
- 1999-06-15 PL PL99344831A patent/PL344831A1/xx unknown
- 1999-06-15 HU HU0102300A patent/HUP0102300A3/hu unknown
- 1999-06-15 CA CA002335724A patent/CA2335724A1/fr not_active Abandoned
- 1999-07-30 TW TW088109993A patent/TW513434B/zh not_active IP Right Cessation
-
2000
- 2000-12-13 NO NO20006352A patent/NO20006352D0/no not_active Application Discontinuation
-
2002
- 2002-02-22 HK HK02101333.2A patent/HK1039780A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1309657A (zh) | 2001-08-22 |
| CA2335724A1 (fr) | 1999-12-23 |
| MY118652A (en) | 2004-12-31 |
| EP1087978A1 (fr) | 2001-04-04 |
| US7015213B1 (en) | 2006-03-21 |
| IL139954A0 (en) | 2002-02-10 |
| HUP0102300A3 (en) | 2002-10-28 |
| NZ509313A (en) | 2002-11-26 |
| HUP0102300A2 (hu) | 2001-11-28 |
| AR019669A1 (es) | 2002-03-13 |
| FR2779652A1 (fr) | 1999-12-17 |
| AU758206B2 (en) | 2003-03-20 |
| RU2229299C2 (ru) | 2004-05-27 |
| CN100348600C (zh) | 2007-11-14 |
| KR20010052836A (ko) | 2001-06-25 |
| TW513434B (en) | 2002-12-11 |
| JP2002518400A (ja) | 2002-06-25 |
| HK1039780A1 (zh) | 2002-05-10 |
| AU4149599A (en) | 2000-01-05 |
| NO20006352D0 (no) | 2000-12-13 |
| FR2779652B1 (fr) | 2001-06-08 |
| PL344831A1 (en) | 2001-11-19 |
| WO1999065917A1 (fr) | 1999-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20006352L (no) | Anvendelse av diazepiner til fremstilling av medisiner for behandling av patologiske tilstander eller sykdommer som involverer en av veksthormon-frigjöringsinhiberingsfaktor- reseptorene | |
| HUP0302131A2 (hu) | Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények | |
| EE200100010A (et) | Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis | |
| NO20032734D0 (no) | Nye 1,2-difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder nevnte forbindelser og anvendelse avdisse for behandling av sykdommer fra lipidstoffskiftet | |
| EE200100007A (et) | Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis | |
| NO20002113D0 (no) | Nye tricykliske forbindelser og deres anvendelse i medisin, fremgangsmÕte for deres fremstillling og farmasøytiske sammensetninger inneholdende dem | |
| AR005282A1 (es) | Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura. | |
| DE69906518D1 (de) | Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis | |
| HUP0200714A2 (hu) | Gyógyhatású vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| EE200000380A (et) | 11ß-halogeno-7(alfa)-asendatud östratrieenid, neid 11ß-halogeno-7(alfa)-asendatud östratrieene sisaldavate farmatseutiliste preparaatide valmistamise meetodid ja nende kasutamine ravimite valmistamiseks | |
| NO973243D0 (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av gynekologiske sykdommer | |
| NO973884L (no) | Aminosyrepreparater og anvendelse derav for klinisk ernæring | |
| ATE200422T1 (de) | Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität | |
| HUP9904317A3 (en) | Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases | |
| NO323466B1 (no) | Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater | |
| TR200100637T2 (tr) | Yeni doğal ürün türevleri | |
| EP0657167A3 (fr) | Application de l'oenothéine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, les compositions pharmaceutiques le contenant et un procédé de préparation à partir d'Epilobium Parviflorum. | |
| NO973342D0 (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av cerebrale degenerative sykdommer | |
| CA2319542A1 (en) | The treatment of sexual dysfunction in certain patient groups | |
| DE02748548T1 (de) | Calcium-l-threonat zur prävention oder behandlung von knochenfrakturen | |
| IT9019793A0 (it) | Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico | |
| CA2290739A1 (en) | New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy | |
| NO973340D0 (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av fedme | |
| HUP0302535A3 (en) | Peptide compounds, pharmaceutical compositions containing them and their use for treatment of no-mediated diseases | |
| HUP0100542A2 (hu) | Progesztogént és anti-progesztogént tartalmazó kit, eljárás előállítására és a vegyületek alkalmazása fogamzásgátló szer előállítására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |